Inflammatix

Inflammatix develops host response diagnostics that leverage immune system biomarkers to rapidly identify and classify acute infections in emergency department settings. The company's proprietary technology uses bioinformatics, machine learning, and artificial intelligence to interpret mRNA immune signatures, enabling clinicians to distinguish bacterial from viral infections and assess illness severity. TriVerity, their FDA-cleared flagship product, provides three actionable diagnostic scores: bacterial infection likelihood, viral infection likelihood, and all-cause illness severity (risk of progression to mechanical ventilation, vasopressors, or renal replacement therapy within seven days). Unlike pathogen-targeting tests, Inflammatix's approach measures circulating immune cell signatures generated by localized infections, improving sensitivity for early detection. The technology is clinically validated and addresses critical gaps in rapid, accurate triage and decision-making when certainty is limited. The company serves emergency departments and acute care settings, with regulatory clearance from the FDA and operations in the United States and Europe.